索磷布韦联合利巴韦林治疗12-17岁基因2型或3型丙型肝炎病毒感染青少年
该研究评估索磷布韦联合利巴韦林治疗12-17岁基因2型或3型慢性丙型肝炎青少年的安全性和有效性,52例患者接受索磷布韦400mg每日一次联合基于体重的利巴韦林治疗12周(基因2型)或24周(基因3型),总体持续病毒学应答12周(SVR12)率为98%(51/52;95%CI 90%-100%),最常见不良事件为恶心(27%)和头痛(23%),药代动力学暴露在预设等效范围内。
要点
- 索磷布韦联合利巴韦林治疗12-17岁基因2型或3型慢性丙型肝炎,总体SVR12率98%(51/52)。
- 基因2型SVR12率100%(13/13),基因3型SVR12率97%(38/39)。
- 最常见不良事件为恶心(27%)和头痛(23%),药代动力学暴露在预设等效范围内。
核心结论
- 索磷布韦联合利巴韦林在12-17岁基因2型或3型慢性丙型肝炎病毒感染青少年中安全且高度有效。
研究设计与样本
- 研究纳入52例12-17岁基因2型或3型丙型肝炎病毒感染青少年,接受索磷布韦400mg每日一次联合基于体重的利巴韦林每日两次,基因2型治疗12周、基因3型治疗24周。
- 主要疗效终点为治疗结束后12周持续病毒学应答(SVR12)率。
- 对前10例入组患者在治疗第7天进行密集血浆采样评估索磷布韦及其代谢物GS-331007的药代动力学,所有患者治疗期间进行稀疏采样。
主要发现
- 患者中位年龄15岁,75%为基因3型,83%为初治,73%经垂直传播感染,40%评估为无肝硬化,其余未确定肝硬化状态。
- 总体SVR12率为98%(51/52;95%置信区间90%-100%)。
- 基因2型患者SVR12率为100%(13/13),基因3型患者SVR12率为97%(38/39)。
- 唯一未达到SVR12的患者在达到SVR4后失访。
- 最常见不良事件为恶心(27%)和头痛(23%)。
关键数值与推荐
- 总体SVR12率为98%(51/52;95%置信区间90%-100%)。
- 基因2型SVR12率为100%(13/13);基因3型SVR12率为97%(38/39)。
- 索磷布韦和GS-331007在青少年中的曲线下面积和最大浓度在预设药代动力学等效边界50%-200%内。
临床怎么用
- 索磷布韦400mg每日一次联合基于体重的利巴韦林每日两次,基因2型治疗12周、基因3型治疗24周,在12-17岁基因2型或3型慢性丙型肝炎青少年中安全且高度有效。
局限性
- 唯一未达到SVR12的患者在达到SVR4后失访。
- 40%的患者评估为无肝硬化,其余患者未确定肝硬化状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Children with chronic hepatitis C virus infection have limited treatment options. We evaluated the all-oral combination of sofosbuvir and ribavirin in adolescents aged 12-17 with hepatitis C virus genotype 2 or 3 (ClinicalTrials.gov NCT02175758). Fifty-two patients received sofosbuvir 400 mg once daily and weight-based ribavirin twice daily for 12 (genotype 2) or 24 (genotype 3) weeks. The pharmacokinetics of sofosbuvir and its metabolite GS-331007 were evaluated by intensive plasma sampling at day 7 in the first 10 patients enrolled and by sparse sampling in all patients throughout treatment. The primary efficacy endpoint was the percentage of patients with a sustained virologic response 12 weeks after treatment (SVR12). The median age of patients was 15 years, and 75% had genotype 3. Eighty-three percent of patients were treatment-naive, and 73% were infected by vertical transmission. Forty percent were assessed as not having cirrhosis; the remainder did not have a cirrhosis determination. Overall, SVR12 was achieved by 98% of patients (51/52; 95% confidence interval, 90%-100%). SVR12 rates were 100% (13/13) for patients with genotype 2 and 97% (38/39) for those with genotype 3. The single patient who did not achieve SVR12 was lost to follow-up after achieving SVR4. The most commonly reported adverse events were nausea (27%) and headache (23%). When compared with the exposure in adults treated in phase 2 and 3 sofosbuvir studies, the area under the curve and maximum concentration for sofosbuvir and GS-331007 in adolescents were within predefined pharmacokinetic equivalence boundaries of 50%-200%. CONCLUSION: Sofosbuvir and ribavirin was safe and highly effective in adolescents with chronic hepatitis C virus genotype 2 or 3 infection. (Hepatology 2017;66:1102-1110).
引用
- Wirth S, Rosenthal P, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017. PMID: 28543053. doi:10.1002/hep.29278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。